SANOFI, CELGENE AND BRISTOL-MYERS SQUIBB HAVE BECOME ASSOCIATED PARTNERS

NEXT formally presented Sanofi, Celgene and Bristol-Myers Squibb as associated partners at the MedWatch morning meeting on 7 February 2017: ‘Learn more about next steps in the large public-private venture’. Hereby, NEXT expands with a new type of partnership for companies wishing to participate in the partnership collaboration on clinical research and get access to NEXT’s platform and optimized processes in relation to start-up and conduct of clinical trials.

From left: Anders Thelborg, CEO, Bristol-Myers Squibb; Charlotte Søby Vestergaard, Country Chair, Sanofi; Tina Buhl, Head of Communication & Senior Manager, Celgene; Britta Smedegaard Andersen, NEXT Project director and Thomas Kongstad Petersen, Chairman of NEXT steering committee at the MedWatch morning meeting 7 February, 2017, where the associates were presented.

NEXT hopes that more companies will follow suit this year.

Charlotte Søby Vestergaard, Country Chair, Sanofi Denmark, says about the collaboration:
“Sanofi looks forward to becoming an associated partner of NEXT. Sanofi has a broad and diverse pipeline, which fits well into the NEXT focus areas. Therefore, Sanofi expects good synergy with the NEXT partnership adding the possibility to attract early clinical trials within several disease areas. In close cooperation with NEXT, Sanofi also gets the opportunity to focus on new areas such as diabetes and cardiovascular diseases, areas in which Sanofi has a long history of research and development of new and innovative treatments. Furthermore, one potential positive aspect for Sanofi could be a collaboration within rare diseases where Denmark has unique opportunities to take a leading position at an international level.”

Also for Celgene it has been important to reinforce their interest in joining NEXT as an associated partner:
“Through the partnership with NEXT, we get the opportunity to contribute to further strengthening Denmark’s position within clinical research. At Celgene we believe that with the strong infrastructure provided by NEXT, we can attract more clinical trials to Denmark, especially studies in the important early phase. However, at the end of the day, hopefully it will be the individual patient, who will gain when Denmark is strengthened as a research nation,” says Bengt Gustavsson, Medical Director, Celgene.

And Bristol-Myers Squibb says:
“Bristol-Myers Squibb conduct numerous clinical trials in Denmark, and for us it has been an obvious decision to join the NEXT collaboration. We hope that it will contribute to attracting more clinical trials to Denmark, both for the benefit of patients with a serious illness such as cancer, and for the many doctors and nurses (and other health professionals) who will carry out these trials, “says Anders Thelborg, CEO of Bristol-Myers Squibb Denmark.